Anti-SARS-Cov-2 antibodies derived from 2GHW
AssigneeCentivax, Inc.
InventorsJacob Glanville, Shahrad Daraeikia, I-Chieh Wang, Sindy Andrea Liao-Chan, Jean-Philippe Bürckert, Sawsan Youssef
Life of this patent
Estimating the term…
Abstract
This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
Claims16
An antibody or an antigen-binding fragment that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that comprises a variable heavy chain (VH) complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO:
- 39;
- a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 53;
- a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 68;
- a variable light chain (VL) CDR1 having an amino acid sequence of SEQ ID NO:
- 7;
- a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 15;
- and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 25.
An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises a VH having an amino acid sequence of SEQ ID NO:
- 81 and a VL having an amino acid sequence of SEQ ID NO:
- 93.
An antibody or an antigen-binding fragment that selectively binds to a SARS-CoV-2, that comprises:
- (i) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 41, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 55, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 70, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 9, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 14, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 23;
- (ii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 32, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 46, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 61, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 4, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 13, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 20;
- (iii) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 36, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 50, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 65, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 6, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 14, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 23;
- or
- (iv) a VH CDR1 having an amino acid sequence of SEQ ID NO:
- 30, a VH CDR2 having an amino acid sequence of SEQ ID NO:
- 44, a VH CDR3 having an amino acid sequence of SEQ ID NO:
- 59, a VL CDR1 having an amino acid sequence of SEQ ID NO:
- 4, a VL CDR2 having an amino acid sequence of SEQ ID NO:
- 13, and a VL CDR3 having an amino acid sequence of SEQ ID NO:
- 20.
Dependencies are inferred from the claim text.